For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 33,478 | |||
| General and administrative | 15,850 | |||
| Total operating expenses | 49,328 | |||
| Loss from operations | -49,328 | |||
| Interest income, net | 6,536 | |||
| Other expense, net | -31 | |||
| Interest expense | 0 | |||
| Total other income, net | 6,505 | |||
| Loss before income taxes | -42,823 | |||
| Income tax benefit | -64 | |||
| Net loss | -42,759 | |||
| Basic EPS | -0.32 | |||
| Diluted EPS | -0.32 | |||
| Basic Average Shares | 134,747,198 | |||
| Diluted Average Shares | 134,747,198 | |||
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)